Jose Pleitez, MD
Family Medicine · Oxnard, CANPI 1902969967
Payments from drug & device makers
Across 759 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$2K
- Amgen$2K
- Novo Nordisk$1K
- Astellas Pharma US Inc$1K
- Boehringer Ingelheim$1K
- plus $5K from 29 others
What the payments were for
- Food & beverage$14,92799%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 123 | $2,456 |
| Lilly USA, LLC | 103 | $1,749 |
| Amgen | 73 | $1,548 |
| Novo Nordisk | 78 | $1,314 |
| Astellas Pharma US Inc | 58 | $1,307 |
| Boehringer Ingelheim | 56 | $1,246 |
| Pfizer | 30 | $617 |
| Sanofi-aventis U.S. LLC | 29 | $606 |
| Bayer | 26 | $573 |
| Merck | 27 | $461 |
| GSK | 21 | $440 |
| AbbVie(2 entities) | 20 | $356 |
| Novartis | 15 | $343 |
| Amarin Pharma, Inc. | 15 | $270 |
| Mannkind Corporation | 12 | $253 |
| Johnson & Johnson | 14 | $218 |
| Medicure Pharma Inc. | 3 | $212 |
| Abbott | 8 | $162 |
| Radius Health, Inc. | 6 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $112 |
| Dexcom, Inc. | 4 | $104 |
| Medtronic(2 entities) | 2 | $61 |
| Eisai Inc. | 3 | $61 |
| Ardelyx, Inc. | 2 | $58 |
| Sanofi Pasteur Inc. | 2 | $42 |
| Corcept Therapeutics | 2 | $33 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Linus Health, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$140
- BREZTRI$140
- FARXIGA$140
- HMG-CoA reductase inhibitor.$138
- RYBELSUS$102
How this compares
$15,056 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 163 | $139,786 |
| TrulicityDulaglutide | 122 | $135,057 |
| JardianceEmpagliflozin | 116 | $104,711 |
| OzempicSemaglutide | 86 | $93,169 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 31 | $73,230 |
| TradjentaLinagliptin | 46 | $39,033 |
| MyrbetriqMirabegron | 65 | $35,486 |
| RybelsusSemaglutide | 37 | $34,294 |
| EliquisApixaban | 27 | $31,451 |
| JanuviaSitagliptin Phosphate | 28 | $27,019 |
| ProliaDenosumab | 13 | $22,573 |
| XareltoRivaroxaban | 38 | $22,198 |
| MounjaroTirzepatide | 19 | $19,920 |
| DapagliflozinDapagliflozin Propanediol | 17 | $10,400 |
| VascepaIcosapent Ethyl | 23 | $9,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Stiolto Respimat | $1,246 | $158,457186 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,749 | $154,977141 claims |
| AstraZenecaFarxiga | $2,456 | $139,786163 claims |
| Novo NordiskOzempic, Rybelsus | $1,314 | $127,463123 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,548 | $95,80344 claims |
| Astellas Pharma US IncMyrbetriq | $1,307 | $35,48665 claims |
| MerckJanuvia, Janumet | $461 | $33,55740 claims |
| PfizerEliquis | $617 | $31,45127 claims |
| Johnson & JohnsonXarelto | $218 | $22,19838 claims |
| AbbVieNamzaric, Synthroid | $356 | $8,39439 claims |
| GSKTrelegy Ellipta | $440 | $7,85012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Oxnard
- Augusto FocilOxnard$12.6M
- Suzanne FussellOxnard$8.9M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.